On the Record · Endo International

Endo International acquisitions, on the record

The businesses Endo International bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
BioSpecifics Technologies Corp. Word for word“As further described in Note 5. Acquisitions and Note 12. License and Collaboration Agreements in the Consolidated Financial Statements included in Part IV, Item 15 of this report, we completed our acquisition of BioSpecifics Technologies Corp., a Delaware corporation and a commercial-stage biopharmaceutical company (BioSpecifics) in December 2020.” 10-K for 2021	acquisition	December 2020	—
retail generics business assets Word for word“For example, as further discussed in Note 3. Discontinued Operations in the Consolidated Financial Statements included in Part IV, Item 15 of this report, in 2021, we divested of certain assets related to our retail generics business, as well as certain associated liabilities.” 10-K for 2021	divestiture	in 2021	—
Litha Healthcare Group Limited, certain assets acquired from Aspen Holdings, and Grupo Farmacéutico Somar, S.A.P.I. de C.V. Word for word“In 2017, we divested of both Litha Healthcare Group Limited and certain assets acquired from Aspen Holdings in October 2015 and Grupo Farmacéutico Somar, S.A.P.I. de C.V.” 10-K for 2021	divestiture	2017	—
manufacturing facilities and related assets in Chestnut Ridge, New York and Irvine, California Word for word“As a result of the sale of our manufacturing facilities and related assets in Chestnut Ridge, New York and Irvine, California, as further discussed in Note 3. Discontinued Operations in the Consolidated Financial Statements included in Part IV, Item 15 of this report, our reliance on third party manufacturers has increased and we are working with new third party manufacturers that we have not worked with before.” 10-K for 2021	divestiture	—	—
Auxilium Pharmaceuticals Word for word“Prior to Aralez, Dr. Tursi was Chief Medical Officer and Vice President of Clinical R&D at Auxilium Pharmaceuticals until its acquisition by Endo in 2015.” 10-K for 2021	acquisition	2015	—
Nevakar Injectables, Inc., a subsidiary of Nevakar, Inc. Word for word“In May 2022, we announced that our EVL subsidiary had entered into an agreement to acquire six development-stage RTU injectable product candidates from Nevakar Injectables, Inc., a subsidiary of Nevakar, Inc., for an upfront cash payment of $35.0 million, which was recorded as an Acquired in-process research and development charge in the Consolidated Statements of Operations in the second quarter of 2022.” 10-K for 2022	agreed acquisition	In May 2022	$35.0 million
six development-stage RTU injectable product candidates from Nevakar Injectables, Inc. Word for word“• In May 2022, we announced that we had entered into an agreement to acquire six development-stage RTU injectable product candidates from Nevakar Injectables, Inc., a subsidiary of Nevakar, Inc., for an upfront cash payment of $35.0 million, which was recorded as an Acquired in-process research and development charge in the Consolidated Statements of Operations in the second quarter of 2022.” 10-K for 2023	acquisition	May 2022	$35.0 million

As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year ended	Cash paid for acquisitions (net of cash acquired)	Cash received from selling businesses	Goodwill from acquisitions
2016-12-31	$30.4 million	$10.9 million	$93.6 million
2017-12-31	$0	$223.2 million	—
2018-12-31	$0	$70.4 million	—
2019-12-31	—	$6.6 million	—
2020-12-31	—	$6.7 million	—
2021-12-31	—	$30.3 million	—
2022-12-31	—	$41.4 million	—
2023-12-31	—	$5.1 million	—

Deal filings since 2016

2024-04-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-01-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-08-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-03-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-03-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-10-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-06-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-03-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-03-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-04-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-10-25 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2017-07-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-07-05 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2017-04-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-04-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-05-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement

Read from Endo International’s annual reports (10-K for 2023, 10-K for 2022, 10-K for 2021) and the financial data it files with the SEC, as of 2024-03-06. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.